Foresee Pharmaceuticals Co Ltd Total Assets
Foresee Pharmaceuticals Co Ltd total assets. Based on the latest financial reports, Foresee Pharmaceuticals Co Ltd (6576) holds total assets worth NT$1.57 Billion TWD (≈ $49.33 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Foresee Pharmaceuticals Co Ltd stock valuation for the company's overall valuation and market capitalisation.
Total Assets of Foresee Pharmaceuticals Co Ltd (2017–2024)
Total assets of Foresee Pharmaceuticals Co Ltd from 2017 to 2024. This chart illustrates how Foresee Pharmaceuticals Co Ltd's total assets have evolved over time, based on quarterly financial data. See today's stock price for Foresee Pharmaceuticals Co Ltd for real-time trading data and today's change.
Foresee Pharmaceuticals Co Ltd - Asset Composition Analysis
Foresee Pharmaceuticals Co Ltd Total Assets Breakdown (December 2024)
Foresee Pharmaceuticals Co Ltd total assets breakdown as of December 2024. Foresee Pharmaceuticals Co Ltd's total assets of NT$1.57 Billion consist of 84.2% current assets and 15.8% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 63.3% |
| Accounts Receivable | NT$32.33 Million | 1.5% |
| Inventory | NT$183.87 Million | 8.5% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$0.00 | 0.0% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2017–2024)
This chart illustrates how Foresee Pharmaceuticals Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore 6576 net working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Foresee Pharmaceuticals Co Ltd's current assets represent 84.2% of total assets in 2024, an increase from 82.2% in 2017.
- Cash Position: Cash and equivalents constituted 63.3% of total assets in 2024, down from 64.5% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2017.
- Asset Diversification: The largest asset category is inventory at 8.5% of total assets.
Foresee Pharmaceuticals Co Ltd Competitors by Total Assets
Key competitors of Foresee Pharmaceuticals Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276
|
China | CN¥68.33 Billion |
|
Sandoz Group AG
SW:SDZ
|
Switzerland | CHF22.86 Billion |
|
H Lundbeck A/S
CO:HLUN-B
|
Denmark | Dkr54.01 Billion |
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥30.77 Billion |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
|
China | CN¥17.01 Billion |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518
|
China | CN¥13.68 Billion |
|
Viyash Scientific Limited
NSE:SEQUENT
|
India | Rs17.26 Billion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥5.11 Billion |
Foresee Pharmaceuticals Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.92 | 2.67 | 2.97 |
| Quick Ratio | 2.60 | 2.41 | 2.97 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$825.40 Million | NT$835.42 Million | NT$218.32 Million |
Foresee Pharmaceuticals Co Ltd - Advanced Valuation Insights
This section examines the relationship between Foresee Pharmaceuticals Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 13.34 |
| Latest Market Cap to Assets Ratio | 0.17 |
| Asset Growth Rate (YoY) | 16.0% |
| Total Assets | NT$2.16 Billion |
| Market Capitalization | $368.35 Million USD |
Valuation Analysis
Below Book Valuation: The market values Foresee Pharmaceuticals Co Ltd's assets below their book value (0.17x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Foresee Pharmaceuticals Co Ltd's assets grew by 16.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Foresee Pharmaceuticals Co Ltd (2017–2024)
The table below shows the annual total assets of Foresee Pharmaceuticals Co Ltd from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$2.16 Billion ≈ $68.03 Million |
+15.99% |
| 2023-12-31 | NT$1.86 Billion ≈ $58.65 Million |
+42.75% |
| 2022-12-31 | NT$1.30 Billion ≈ $41.08 Million |
-20.56% |
| 2021-12-31 | NT$1.64 Billion ≈ $51.71 Million |
-21.82% |
| 2020-12-31 | NT$2.10 Billion ≈ $66.15 Million |
+108.04% |
| 2019-12-31 | NT$1.01 Billion ≈ $31.80 Million |
+61.58% |
| 2018-12-31 | NT$624.61 Million ≈ $19.68 Million |
-11.16% |
| 2017-12-31 | NT$703.10 Million ≈ $22.15 Million |
-- |
About Foresee Pharmaceuticals Co Ltd
Foresee Pharmaceuticals Co., Ltd. operates as biopharmaceutical company in the United States, China, and Europe. The company's stabilized injectable formulation pipeline includes FP-001, which completed Phase III clinical study for the treatment of advanced stage prostate cancer; FP-004 that is in preclinical stage to treat opioids use disorder; FP-011 and FP-014, a long-acting sustained release … Read more